Abstract
The main drawback of most cancer chemotherapy is its relatively low ability to target tumour cells versus normal cells. As a consequence, chemotherapy is usually connected with severe side effects due to the toxicity of traditional cytostatic agents towards normal tissues. A few years ago, the site-specific activation of non-toxic prodrugs in tumours has been proposed in order to enhance the selectivity for the killing of cancer cells. Within this framework, most of the prodrugs that have been designed were three part compounds comprising trigger, linker and effector units. The main function of the linker is to release the effector unit after selective trigger activation via a spontaneous chemical breakdown. However, its structure also affects significantly many prodrug properties such as stability, pharmacokinetic, organ distribution, bioavailability or trigger activation. This review, focussed on the linker unit, is an update of our previous article published in 2002. It deals with recent advances in the design of prodrug linkers including new delivery systems such as elongated linkers or selfimmolative dendrimers.
Keywords: tumour cells, cancer chemotherapy, cytostatic agents, Self-Immolative Linkers, trigger, linker
Anti-Cancer Agents in Medicinal Chemistry
Title: Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy
Volume: 8 Issue: 6
Author(s): I. Tranoy-Opalinski, A. Fernandes, M. Thomas, J.-P. Gesson and S. Papot
Affiliation:
Keywords: tumour cells, cancer chemotherapy, cytostatic agents, Self-Immolative Linkers, trigger, linker
Abstract: The main drawback of most cancer chemotherapy is its relatively low ability to target tumour cells versus normal cells. As a consequence, chemotherapy is usually connected with severe side effects due to the toxicity of traditional cytostatic agents towards normal tissues. A few years ago, the site-specific activation of non-toxic prodrugs in tumours has been proposed in order to enhance the selectivity for the killing of cancer cells. Within this framework, most of the prodrugs that have been designed were three part compounds comprising trigger, linker and effector units. The main function of the linker is to release the effector unit after selective trigger activation via a spontaneous chemical breakdown. However, its structure also affects significantly many prodrug properties such as stability, pharmacokinetic, organ distribution, bioavailability or trigger activation. This review, focussed on the linker unit, is an update of our previous article published in 2002. It deals with recent advances in the design of prodrug linkers including new delivery systems such as elongated linkers or selfimmolative dendrimers.
Export Options
About this article
Cite this article as:
Tranoy-Opalinski I., Fernandes A., Thomas M., Gesson J.-P. and Papot S., Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133065
DOI https://dx.doi.org/10.2174/187152008785133065 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Genome-Wide Expression Analysis in Epilepsy: A Synthetic Review
Current Topics in Medicinal Chemistry Telomeres, Genomic Instability, DNA Repair and Breast Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Astatine-211: Production and Availability
Current Radiopharmaceuticals Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets Osteosarcoma of the Jaws: A Literature Review
Current Medical Imaging Editorial (Thematic Issue: Perspectives on Strategies for Overcoming Cancer Therapy Resistance)
Current Protein & Peptide Science Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation
Current Topics in Medicinal Chemistry Breastfeeding and Diabetes
Current Diabetes Reviews Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
Current Drug Metabolism Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Production of High-purity Radium-223 from Legacy Actinium-Beryllium Neutron Sources
Current Radiopharmaceuticals